1h Free Analyst Time
High-Grade Glioma - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
This latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H2 2019, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.
Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 1, 28, 19, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Unknown stages comprises 3, 2, 3 and 1 molecules, respectively.
High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionHigh-Grade Glioma - Overview
High-Grade Glioma - Therapeutics Development
High-Grade Glioma - Therapeutics Assessment
High-Grade Glioma - Companies Involved in Therapeutics Development
High-Grade Glioma - Drug Profiles
High-Grade Glioma - Dormant Projects
High-Grade Glioma - Discontinued Products
High-Grade Glioma - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for High-Grade Glioma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
High-Grade Glioma - Pipeline by Aadi Bioscience Inc, H2 2019
High-Grade Glioma - Pipeline by Advanz Pharmaceutical Corp, H2 2019
High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H2 2019
High-Grade Glioma - Pipeline by AngioChem Inc, H2 2019
High-Grade Glioma - Pipeline by Apollomics Inc, H2 2019
High-Grade Glioma - Pipeline by Athenex Inc, H2 2019
High-Grade Glioma - Pipeline by Bayer AG, H2 2019
High-Grade Glioma - Pipeline by BeiGene Ltd, H2 2019
High-Grade Glioma - Pipeline by Berg LLC, H2 2019
High-Grade Glioma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2019
High-Grade Glioma - Pipeline by Biomimetix JV LLC, H2 2019
High-Grade Glioma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
High-Grade Glioma - Pipeline by Bristol-Myers Squibb Co, H2 2019
High-Grade Glioma - Pipeline by Cellectar Biosciences Inc, H2 2019
High-Grade Glioma - Pipeline by Curis Inc, H2 2019
High-Grade Glioma - Pipeline by Curtana Pharmaceuticals Inc, H2 2019
High-Grade Glioma - Pipeline by DNAtrix Inc, H2 2019
List of Figures
Number of Products under Development for High-Grade Glioma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aadi Bioscience Inc
- Advanz Pharmaceutical Corp
- Advenchen Laboratories LLC
- AngioChem Inc
- Apollomics Inc
- Athenex Inc
- Bayer AG
- BeiGene Ltd
- Berg LLC
- Bio-Cancer Treatment International Ltd
- Biomimetix JV LLC
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Cellectar Biosciences Inc
- Curis Inc
- Curtana Pharmaceuticals Inc
- DNAtrix Inc
- Eisai Co Ltd
- EpicentRx Inc
- Erimos Pharmaceuticals LLC
- Everfront Biotech Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Genor BioPharma Co Ltd
- GtreeBNT Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Ipsen SA
- Karyopharm Therapeutics Inc
- Mana Therapeutics Inc
- Millennium Pharmaceuticals Inc
- MimiVax LLC
- NewLink Genetics Corp
- Northwest Biotherapeutics Inc
- Novartis AG
- Oncoceutics Inc
- Oncotelic Inc
- Ono Pharmaceutical Co Ltd
- Pfizer Inc
- Prelude Therapeutics Inc
- PTC Therapeutics Inc
- Regeneron Pharmaceuticals Inc
- Sumitomo Dainippon Pharma Co Ltd
- Targepeutics Inc
- Tessa Therapeutics Pte Ltd
- TheraBiologics Inc
- TVAX Biomedical Inc
- ZIOPHARM Oncology Inc
